Thursday, 12 September 2024

16:00 Registration
18:00 Welcome Reception (18:00-20:00)

Friday, 13 September 2024

08:00 Registration
08:30 Opening ceremony

08:45 Session 1. Malformation
- Commonly overlooked ocular signs and symptoms in Down syndrome. C. Parsa (Brussels, Belgium)
- Congenital ectopia lentis in children. G. Daghrouj (Casablanca, Maroc)
- Genotype-Phenotype Correlation Model for the Spectrum of OCA1-associated Albinism. M. Bjelos (Zagreb, Croatia)
- Optical Coherence Tomography Angiography Assessment in Congenital Aniridia. A. Dentel. (Paris, France)
- Transcriptome analysis of patient derived microphthalmia and myopia optic vesicles identifies key pathways influencing axial length. D Jackson (London, UK)
- Novel sling baby technique for fundus imaging. M. Khan (Birmingham, UK)

09:35 Session 2a. Retinopathy of prematurity: current issues and treatments
- Enhancing the ROP risk profile through structured evaluation of placental inflammation and uteroplacental malperfusion. S. El Emrani (Leiden, Netherlands)
- DIGIROP-Screen model for screening retinopathy of prematurity: a Portuguese retrospective cohort. M. Goncalves (Lisboa, Portugal)
- Screening at-risk ROP patients: Use of a single small field image centred on the optic disc. Y. Borella (Paris, France)
- Validation of a RetCam™-trained deep learning algorithm for retinopathy of prematurity on Phoenix ICON™ images. L. Derks (Rotterdam, Netherlands)
- To evaluate the Dutch organization of care of infants who have been treated for severe Retinopathy of Prematurity: a nationwide prospective multicenter study. A. Arends-Tijam (Rotterdam, Netherlands)
- Postoperative global and perilesional vessel changes in retinopathy of prematurity: a comparison between laser and anti-VEGF treatment. F. Catania (Paris, France)
- Anti-VEGF in Retinopathy of Prematurity: a French experience in micropreterms babies. How does it change our practice? A. Barjol (Paris, France)
- Macular changes by optical coherence tomography after ranibizumab treatment in type 1 retinopathy of prematurity. Hosny R. (Cairo, Egypt)
- Outcomes of modified limbal lensectomy-vitrectomy in stages 4B and 5 retinopathy of prematurity with extended retrolental fibroplasia. I. Chehaibou (Paris, France)

10:30 Coffee Break, exhibition and poster viewing

11:15 Session 2b. Retinopathy of prematurity: current issues and treatments
- Development and validation of a early diagnostic protocol for Cerebral Visual Impairment in extreme preterm infants. M. Vilella (Zaragoza, Spain)
- Multifocal ERG showed that macular function was affected in prematurely born young adults. A. Akerblom (Västerås, Suède)
- Refractive error following endoscopic vitrectomy for stage 4 retinopathy of prematurity. K. Williams (London, UK)
- Longitudinal associations between ophthalmological outcome and visual perception in children born very preterm. E. Larsson (Uppsala, Sweden)

Check for the latest update at https://epos2024.org/programme
**Session 3. Metabolic disorders: past, present and future**

- An overview of therapeutic advances in metabolic disorders. M. Schiff (Paris, France)
- How to treat retinal dystrophies in CLN? R. Henderson (London, UK)
- Intravitreal enzyme replacement therapy in late infantile CLN2 disease slows down CLN2 retinopathy. C. Priglinger (Munich, Germany)
- Safety and efficacy of Cystadrops® eye-drop solution taken over a 90-day period in nephropathic cystinosis patients aged from 6 months to <2 years. S. Biswas (Manchester, UK)
- The use of Cystadrops® as a novel therapy in the treatment of Belgian cystinosis patients. E. Matthys (Leuven, Belgium)
- Optic neuropathy in infants: should we stop at MRI? H. Bouvarel (Lyon, France)
- Visual Prognosis in Infantile Malignant Osteopetrosis. S. Kerkouri (Paris, France)
- Systematic study of ophthalmological findings in 10 patients with PEX1-mediated Zellweger. J. Karuntu (Leiden, Netherlands)

**Lunch break**

**Session 4. Retina**

- Selective chemotherapy in retinoblastoma treatment in Hungary. E. Maka (Budapest, Hungary)
- How the Covid pandemic helped us to have a retinoblastoma center in Bucharest. EC Nitulescu (Bucharest, Romania)
- The large clinical spectrum of CSNB in childhood. I. Audo (Paris, France)
- NR2E3- retinal dystrophies: a retrospective study from a large French Inherited Retinal Dystrophy cohort. G. Hallali (Paris, France)
- Genotype-Phenotype Correlation in RDH12-Associated Retinal Dystrophy: the Significance of Watercolored Fundi as a Predictor of Preserved Vision. A. Curic (Zagreb, Croatia)
- Visual outcome and ocular characteristic in children with Alagille syndrome. K. Tear (Stockholm, Sweden)
- Value and limits of the prolonged scotopic adaptation proceeding full-field electroretinogram and molecular genetic findings to diagnose Fundus Albipunctatus. E. Laumonier (Paris, France)

**Session 5. Orbit, adnexae, surface**

- Nasal endoscopic controlled bicanalicular silicone stent intubation in congenital lacrymal system stenosis. S. Markelj (Škofja Loka, Slovenia)
- To Scan or Not to Scan - A Subdural Empyema Case Series. T. Boote (Glasgow, UK)
- Pediatric Graves’ orbitopathy: a case series of 11 children. A. Lachelah (Paris, France)
- Systemic treatment with Cyclosporine A in children with severe vernal keratoconjunctivitis. I Gazit (Tzrifin, Israël)
- Side effects of tacrolimus after treatment of allergic conjunctivitis in children. A. Nemet (Givat, Israël)
- Plasminogen eyedrops in ligneous conjunctivitis due to plasminogene deficiency. M. Desira (Marseille, France)

**Coffee break with poster tour n°1**

**Session 6. Inflammatory disorders**

- A consecutive case series of paediatric cytomegalovirus retinitis in a single centre quaternary paediatric hospital. O. Warda (London, UK)
- Imaging predictors of time to resolution of macular edema in pediatric intermediate uveitis. C. Barresi (Paris, France)
- Occult capillaritis in pediatric idiopathic panuveitis: a new fluorangiographic prognostic biomarker. F. Catania (Paris, France)
- The step-up treatment approach in paediatric uveitis: Safety and efficacy analysis in a large Swiss cohort. J. Gunzinger (Zurich, Switzerland)
- Pediatricians’ knowledge, attitude and practice on treating children with red eye disease. D. Mostovoy (Modiin, Israël)

**EPOS-WSPOS joint symposium on myopia** - With Prs Hildebrand, Lagrèze, Bremond, Nischal & Rozema

**End of first day scientific programme**

**GALA DINNER (Optionnal Registration)**

Check for the latest update at https://epos2024.org/programme
Saturday, 14 September 2024

08:30 **Session 7. Retinal Surgery**
- Persistent fetal vasculature and familial exudative vitreoretinopathy: comparison of two cases. E. Vermeersch (Leuven, Belgium)
- Laser pointer induced Choroidal Neovascular Membranes in Children: A case series highlighting this ongoing public health danger in children. A. Shafi (Wakefield, UK)
- Retrospective case series to describe outcomes of conservative and surgical management of patients with Norrie Disease. O. Warda (London, UK)
- Risk factors for retinal detachment in Marfan syndrome after pediatric lens removal. T. Chapron (Paris, France)
- Complications following vitrectomy for paediatric optic disc pit maculopathy (ODPM). A. di Domenico (Oxford, UK)
- Retinal detachment risk and outcomes in ocular coloboma from a large UK cohort. D. Jackson (London, UK)

09:15 **Session 8. Congenital and infantile cataracts: intervention controversies**
- Persistent fetal vasculature: clinical patterns and literature review. T. Hadjistilianou (Siena, Italy)
- Intraocular lens power calculation for optic capture in pediatric eyes. D. Knebel (Munich, Germany)
- How to keep the visual axis clear after an early congenital operation? MT. Pompe (Ljubljana, Slovenia)
- Bag-in-the-lens surgery in paediatric cataracts. MJ. Tassignon (Antwerp, Belgium)
- Congenital cataract surgery: Factors influencing successful Bag-in-the-lens implantation in children under 6 years. C. Bonifas (Toulouse, France)
- Post-operative outcomes in bag-in-the-lens technique versus standard lens-in-the-bag procedure in congenital cataract surgery in children under 6 years of age. L. Lequeux (Toulouse, France)
- The Swedish National Pediatric Cataract Register (PECARE): Lessons learned from studies of the first 1000 eyes in the past 16 years. G. Magnusson (Malmö, Sweden)
- Registration of pediatric cataract operations using a new registry: EuReCCa. E. Ghyczy (Amsterdam, Netherlands)

10:25 **Coffee break and poster tour n°2**

11:10 **Session 9. Neuro-ophthalmology**
- A case series of optic neuropathy caused by vitamin A deficiency in children. C. Bourke (London, UK)
- MOG - associated disease and raised intracranial pressure in childhood. V. Panteli (London, UK)
- Paediatric disc dilemmas; How we can use technology to effectively safety net. T. Lloyd (Leeds, UK)
- Optic atrophy evolution in children with Triple A (Allgrove) syndrome. T. Ben Salah (Brussels, Belgium)
- Modified Frisén Scale grades 1 and 2 are not specific for papilloedema in the paediatric population. A. Houtman (Glasgow, UK)
- Paediatric intracranial hypertension: a case series at a UK Teaching Hospital. M. Seelarbokus (Wakefield, UK)
- The internal visual crowding: impact of retina asymmetry on vision mechanisms, consequences and how to correct it. M. Kodochian (Beaune, France)
- Ophthalmological Manifestations in KCNQ2-Related Disorders: A Retrospective Case Series Study. K. Mairot (Marseille, France)
- Correlation of disturbances in spatial adaptation of gaze (strabismus) and amblyopia with changes in neuro-reflex excitability and metabolic disorders in PPE. S. Salmanova (Baku, Azerbaijan)
- Low vision aids in Pediatric Leber Hereditary Optic Neuropathy: experience of a tertiary center. C. Costa (Coimbra, Portugal)
- Medical condition peculiarities among school age children with visual impairment. N. Kuzmin (Cheboksary, Russia)
- Ophthalmic manifestations in pediatric population of Neurofibromatosis-1 in Latvia, multidisciplinary approach. E. Salmane-Sapale (Riga, Latvia)

12:25 **Assembly of EPOS Members**

13:00 **Lunch break**

14:00 **Session 10. Gene therapy**
- What’s in the pipelines for the next few months? G. Lemuer (Nantes, France)
- Surgery for gene therapy: how to reach the target? A. Daruich-Matet (Paris, France)
- A cross-sectional study on retinal dystrophies in children seen over one year in a reference center. G. Mesa (Paris, France)

Check for the latest update at [https://epos2024.org/programme](https://epos2024.org/programme)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 11. Surface, cornea &amp; Glaucoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:35</td>
<td>Classifying corneal congenital opacities. (K. Nischal, Pittsburgh, USA)</td>
</tr>
<tr>
<td></td>
<td>New trends in infantile glaucoma. (P. Dureau, Paris, France)</td>
</tr>
<tr>
<td></td>
<td>Aphakic glaucoma in children. A. El Kettani, (Casablanca, Morocco)</td>
</tr>
<tr>
<td></td>
<td>Glaucoma syndromic disorders. Z. Laftimi (Casablanca, Morocco)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Coffee Break, exhibition and poster viewing</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:20</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 12. Refraction, Amblyopia</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>Cycloplegic eyedrops and side effects. N. Schalij-Delfos (Leiden, Netherlands)</td>
</tr>
<tr>
<td></td>
<td>Presenting features, assessment, progression rates and underlying aetiology in infants and young children presenting with high myopia. A. Dahlmann-Noor (London, UK)</td>
</tr>
<tr>
<td></td>
<td>OPHTAMYOP study myopia control in French children treated with defocus DIMS spectacles: interim analysis. D. Bremond-Gignac (Paris, France)</td>
</tr>
<tr>
<td></td>
<td>Visual acuity test, refractive error (without mydriasis) and strabismus in 500 children aged 6-10 years in Poland - are we surprised? M. Szwajkowska (Olsztyn, Poland)</td>
</tr>
<tr>
<td></td>
<td>CureSight Binocular Amblyopia Treatment - One Year follow up. O. Yehezkel (Ramat Gan, Israël)</td>
</tr>
<tr>
<td></td>
<td>The CroMyop Study: Myopia Progression in Croatian Children and Adolescents and the Development of an Advanced Predictive Model. A. Varosanec (Zagreb, Croatia)</td>
</tr>
<tr>
<td></td>
<td>0.05% atropine for myopia treatment in Estonia: nine-month treatment effect and tolerability. K. Palumaa (Tallinn, Estonia)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Awards and closing ceremony</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:43</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>End of conference</td>
</tr>
</tbody>
</table>

Check for the latest update at https://epos2024.org/programme